Moderna (MRNA) calls active into disclosing shipment of mRNA vaccine for Phase 1 coronavirus study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Moderna (MRNA) Tops Q4 EPS by 5c
February 26, 2020 7:16 AM ESTModerna (NASDAQ: MRNA) reported Q4 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $17.37 million.
The Moderna team continues to execute our strategy, including our CMV Phase 2 study enrolling ahead of plan,... More
Moderna (MRNA) Reports First Shipment of mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study
February 25, 2020 5:51 AM ESTModerna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients today announced that it has released the first batch of mRNA-1273, the Companys vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) to be used in the planned Phase 1 study in the U.S.
mRNA-1273 is an mRNA vaccine against the novel... More
